Press Release: NextPlat Reports Third Quarter 2025 Results

Dow Jones
Yesterday

Company Reports $13.8M in Q3 Revenue as Refocusing and Cost Cutting Initiatives Drive Improved Late Quarter Performance with Accelerated Sequential Improvements Expected in Q4 and into 2026

HALLANDALE BEACH, Fla., Nov. 13, 2025 /PRNewswire/ -- NextPlat Corp (NASDAQ: NXPL, NXPLW) ("NextPlat" or the "Company"), a global consumer products and services company providing healthcare and technology solutions through e-commerce and retail channels worldwide, today announced the financial results for the quarter-ended September 30, 2025, reflecting the performance of its e-Commerce and Healthcare Operations.

"Late in the third quarter, we began to see the positive impact of our cost-cutting, customer re-engagement, and business efficiency efforts, reversing the sequential declines witnessed in the first half of 2025. Based upon the significant increased prescription volumes and related revenue recorded in our healthcare segment in early Q4, combined with accelerating cost reductions across the organization, it is clear that our refocusing efforts are delivering the positive impacts we expected, laying the groundwork for much-improved financial results into early 2026," said David Phipps, Chief Executive Officer and President of NextPlat Corp.

Third Quarter 2025 Financial Highlights:

   -- Consolidated revenue for the quarter ended September 30, 2025, was 
      approximately $13.8 million compared to approximately $15.4 million for 
      the quarter ended September 30, 2024. The decrease in consolidated 
      revenue was primarily driven by a decline in Healthcare Operations due to 
      the decrease in pharmacy 340B contract revenue. As a result of direct 
      engagement with select 340B customers late in the quarter, the Company 
      has seen improved prescription volume within this segment which it 
      believes will contribute to sequential increases in 340B prescription 
      volumes starting in the fourth quarter of 2025. 
 
   -- Overall gross profit margin for the quarter ended September 30, 2025, 
      declined to approximately 19.9% from 23.2% when compared to the prior 
      year quarter. Gross profit margin from our Healthcare segment decreased 
      to approximately 18.4% in the third quarter of 2025 from 21.5% in the 
      third quarter of 2024 and was primarily attributable to the decrease in 
      340B revenue. Gross profit margin for our e-Commerce Operations decreased 
      to approximately 23.7% from 28.1% when compared to the prior year quarter 
      primarily due to a service provider airtime contract that expired on 
      December 31, 2024, which introduced new airtime costs beginning January 
      1, 2025, and temporary rate reductions for some customers continuing to 
      be affected by ongoing network provider service interruptions. 
 
   -- Operating expenses for the quarter ended September 30, 2025, decreased to 
      approximately $4.7 million compared to approximately $7.8 million in the 
      prior year quarter, excluding approximately $3.7 million in non-recurring 
      expenses such as an impairment loss from the write-down of certain 
      long-lived assets. As expected, overall operational costs declined due to 
      a decrease in stock-based compensation for grants fully vested, a 
      reduction in executive compensation, and ongoing headcount reductions 
      implemented as part of the Company's proactive steps designed to improve 
      its expense structure. As a result of ongoing operational process 
      efficiency improvements, staff adjustments, and other cost saving efforts, 
      the Company anticipates further reductions in operating expenses which 
      are expected to contribute to continued improvement going forward. 
 
   -- Net loss attributable to NextPlat Corp common shareholders for the 
      quarter ended September 30, 2025, decreased approximately 48% to 
      approximately $2.2 million, or ($0.08) per diluted share, compared to a 
      net loss of approximately $4.2 million, or ($0.22) per diluted share 
      reported for the quarter ending September 30, 2024. 
 
   -- The Company ended the quarter with approximately $13.9 million in cash. 
 
   -- During the third quarter of 2025, the Company began repurchasing its 
      common shares under the authorized share repurchase program. A total of 
      130,549 shares were repurchased and are being held as treasury stock. 

Organizational Highlights and Recent Business Developments:

   -- As communicated in the recent CEO Shareholder Update Letter, the Company 
      continues to execute its plan to refocus and streamline its operations to 
      improve efficiencies and reduce costs while supporting future growth. 
      NextPlat has identified and taken steps to reduce annualized overhead 
      expenses by more than $2.0 million through actions including reduction in 
      staff, operational and logistical improvements, and the elimination of 
      underutilized office space. Although some of these initial cost 
      reductions are included in the financial results for the quarter ended 
      September 30, 2025, the identified savings are expected to increasingly 
      contribute to sequentially improved operating metrics starting in the 
      fourth quarter. At the same time, the Company is allocating a portion of 
      these annual savings to invest into supporting the growth of the business 
      including improved customer service and the recruitment of additional 
      personnel and resources in sales and marketing with an emphasis on 
      securing new 340B and long-term care facility service contracts. 
 
   -- Under the leadership of its newly expanded Healthcare team, the Company 
      has been implementing operational improvements focused on efficiency, 
      enhanced customer service, and business development. These efforts are 
      highlighted by the addition of new customers during the quarter as well 
      as a recently expanded medication fulfillment services subcontract on 
      behalf of a government contractor previously awarded to the Company. This 
      subcontract and renewed activity by new and existing 340B customers are 
      contributing to a significant increase in additional high margin 
      prescription volumes, currently exceeding 3,000+ per month. This 
      increased activity and momentum continued through October and into early 
      November and is currently anticipated to drive a significant sequential 
      prescription volume increase in the fourth quarter vs. the third quarter 
      of 2025 and into 2026. The Company is also currently working to optimize 
      inventory levels in its PharmcoRx pharmacies, which are expected to 
      generate a significant one-time cash savings through the return of excess 
      inventory to the supplier. 
 
   -- In the e-Commerce segment, during the quarter, the Company continued to 
      see robust sales for satellite-based connectivity and IoT (Internet of 
      Things) products with strength on the Amazon platform and in high-margin 
      recurring revenue which continues to run at record levels. Through its 
      Global Telesat Communications Ltd (GTC) and U.S.-based Orbital Satcom and 
      Outfitter Satellite units, the Company continues to expand its portfolio 
      of cutting-edge connectivity products and growing its consumer and 
      enterprise customer base with new and existing relationships, highlighted 
      by the selection of GTC as the exclusive distributor for personal 
      messaging and tracking products by a leading global satellite network 
      operator for countries in the Nordic region. In its e-Commerce 
      development program for the sale of OPKO Healthcare $(OPK)$ 
      ("OPKO")-branded human health and wellness products in China, despite 
      continued challenges of limited inventory levels, sales activity and 
      sell-through remains high. In September, NextPlat also launched its 
      Florida Sunshine products in the UK and EU and began processing orders 
      via its Amazon and Shopify e-commerce storefronts. The Company is also 
      preparing the launch of an Artificial Intelligence (AI)-driven marketing 
      campaign for Florida Sunshine in partnership with an experienced 
      healthcare brand marketing firm and its storefront on Alibaba Group 
      Holding Limited's (NYSE: BABA) Tmall store in China has been approved to 
      sell its products with shipping expected to begin in the first quarter of 
      2026. 

Third Quarter 2025 Conference Call Notification

NextPlat's Chief Executive Officer and President, David Phipps, its Chief Financial Officer, Amanda Ferrio, and Vice President of Healthcare Operations, Birute Norkute, will host a conference call today, November 13(th) at 8:30 a.m. Eastern time to discuss the results for the quarter ended September 30, 2025, as well as other recent developments.

To access the call, please use the following information:

 
Date:                           Thursday, November 13, 2025 
Time:                           8:30 a.m. Eastern time 
Toll-free dial-in number:       1-800-836-8184 
International dial-in number:   1-646-357-8785 
Conference webcast link:        https://app.webinar.net/EYVam5wPR3y 
 

Please call the conference telephone number 5-10 minutes prior to the start time. An operator will register your name and organization.

The conference call will be broadcast live and available for replay at https://app.webinar.net/EYVam5wPR3y and via the investor relations section of the Company's website at https://ir.nextplat.com/news-events/ir-calendar/detail/20251113-q3-2025-results-conference-call. A replay of the conference call will be available after 12:00 p.m. Eastern time through November 20, 2025.

 
Toll-free replay number:        1-888-660-6345 
International replay number:    1-646-517-4150 
Replay entry code:              03432 # 
 

(MORE TO FOLLOW) Dow Jones Newswires

November 13, 2025 08:03 ET (13:03 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10